News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,968 Results
Type
Article (8016)
Company Profile (140)
Press Release (476811)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166745)
Career Advice (305)
Deals (25738)
Drug Delivery (7)
Drug Development (52876)
Employer Resources (14)
FDA (9760)
Job Trends (8574)
News (238191)
Policy (17906)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (486)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (97)
Alliances (33154)
ALS (105)
Alzheimer's disease (979)
Antibody-drug conjugate (ADC) (272)
Approvals (10389)
Artificial intelligence (323)
ASCO (159)
Autoimmune disease (208)
Automation (28)
Bankruptcy (263)
Best Places to Work (6958)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (112)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (139)
Brain cancer (29)
Breast cancer (514)
Cancer (3680)
Cardiovascular disease (221)
Career advice (245)
Career pathing (1)
CAR-T (175)
CDMO (7)
Celiac Disease (1)
Cell therapy (479)
Cervical cancer (34)
Clinical research (47919)
Collaboration (1253)
Commercialization (3)
Compensation (1474)
Complete response letters (34)
COVID-19 (757)
CRISPR (64)
C-suite (759)
Cystic fibrosis (85)
Data (5712)
Denatured (4)
Depression (102)
Dermatology (63)
Diabetes (344)
Diagnostics (4192)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (156)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73730)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87700)
Executive appointments (703)
FDA (12423)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (927)
Gene editing (126)
Generative AI (9)
Gene therapy (321)
GLP-1 (291)
Government (945)
Grass and pollen (2)
Guidances (281)
Healthcare (9327)
Hematology (94)
HIV (53)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (59)
Indications (157)
Infectious disease (945)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (258)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (11)
Liver cancer (44)
Longevity (18)
Lung cancer (512)
Lymphoma (253)
Machine learning (27)
Management (3)
Manufacturing (538)
Marketing (8)
MASH (118)
Medical device (8663)
Medtech (8810)
Mergers & acquisitions (14391)
Metabolic disorders (709)
mRNA (59)
Multiple sclerosis (103)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (40)
Neuroscience (1834)
NextGen: Class of 2026 (3150)
Non-profit (842)
Obesity (225)
Opinion (10)
Ovarian cancer (160)
Pain (172)
Pancreatic cancer (201)
Parkinson's disease (201)
Partnered (12)
Patents (480)
Patient recruitment (513)
Peanut (31)
People (41257)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15475)
Phase 2 (21395)
Phase 3 (14427)
Pipeline (7439)
Policy (18)
Postmarket research (1570)
Preclinical (6541)
Press Release (34)
Prostate cancer (191)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (576)
Real estate (3020)
Recruiting (6)
Regulatory (14865)
Reports (21)
Research institute (582)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (101)
Series A (157)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (330)
Venture capital (17)
Weight loss (73)
Women's health (82)
Date
Today (56)
Last 7 days (262)
Last 30 days (1497)
Last 365 days (18954)
2026 (12608)
2025 (19251)
2024 (22986)
2023 (26538)
2022 (34586)
2021 (37176)
2020 (33468)
2019 (23256)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24268)
2014 (21679)
2013 (18138)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (228)
Alabama (74)
Alaska (2)
Arizona (306)
Arkansas (11)
Asia (17916)
Australia (2100)
California (12056)
Canada (3172)
China (530)
Colorado (487)
Connecticut (413)
Delaware (208)
Europe (24644)
Florida (1805)
Georgia (386)
Hawaii (3)
Idaho (46)
Illinois (706)
India (51)
Indiana (317)
Iowa (15)
Japan (409)
Kansas (101)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1206)
Massachusetts (7897)
Michigan (308)
Minnesota (563)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (117)
New Hampshire (60)
New Jersey (2635)
New Mexico (12)
New York (2829)
North Carolina (1291)
North Dakota (4)
Northern California (6048)
Ohio (280)
Oklahoma (14)
Oregon (16)
Pennsylvania (2265)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (77)
South Dakota (1)
Southern California (5008)
Tennessee (121)
Texas (1957)
United States (39118)
Utah (363)
Vermont (1)
Virginia (154)
Washington D.C. (38)
Washington State (933)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
484,968 Results for "lensar inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
August 13, 2026
·
13 min read
Press Releases
LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
August 6, 2026
·
1 min read
Press Releases
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
April 30, 2026
·
1 min read
Press Releases
LENSAR® Reports First Quarter 2026 Results and Provides Business Update
May 8, 2026
·
14 min read
Press Releases
LENSAR® Provides Update on Pending Acquisition by Alcon
February 26, 2026
·
4 min read
Press Releases
LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC
March 16, 2026
·
5 min read
Press Releases
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
March 31, 2026
·
17 min read
Press Releases
Alcon Agrees to Acquire LENSAR, Inc.
March 25, 2025
·
9 min read
Deals
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 2,150 shares of the Company’s common stock.
June 3, 2024
·
1 min read
Press Releases
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 2, 2025
September 3, 2025
·
1 min read
1 of 48,497
Next
